Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H23FN5O6P |
InChIKeyPVRFQJIRERYGTQ-UYISCHNFSA-N |
CAS Registry1231747-17-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C, Chronic | Phase 2 | US | 01 Sep 2011 | |
Hepatitis C, Chronic | Phase 2 | PR | 01 Sep 2011 |